Canagliflozin boosts A1C, beta-cell function in type 2 diabetes

05/6/2013 | Healio

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C rates at 26 weeks compared with those in the placebo group, a study indicated. Researchers also noted improvements in insulin secretion rates and beta-cell function among canagliflozin-treated patients. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ